PubMed Health⌕ Search

Biomedical subjects

M R Alijani

Publications and source records attributed to M R Alijani.

31 records · Page 2Linked to original sources
PubMed1987

Leukotrienes, thromboxane, and platelet activating factor in organ transplantation.

The antirejection eicosanoids--PGE2, (PGD2), and PGI2--have an attenuating effect on T-cell proliferation by inhibition of IL-1, IL-2, and class II antigen expression on macrophages, and the prorejection eicosanoids--TXA2, LTB4, LTC4, and LTD4--enhance T-cell proliferation. LTB4 stimulates IL-1 and IL-2 formation and expression of IL-2 receptor. The mechanism of enhancement of T-cell proliferation by TXA2 has not been demonstrated. LTC4 and LTD4 promote gamma-interferon release and can replace IL-2 as a stimulator of gamma-interferon. PAF at high concentrations inhibits lymphocyte proliferation. The eicosanoids interfere with the same mechanisms as CsA and corticosteroids on T-cell clonal expansion. In experimental organ transplantation, corticosteroids can be replaced by compounds preventing the formation or expression of the prorejection eicosanoids or analogs of antirejection eicosanoids as well as by PAF antagonists. In addition, these drugs exert synergistic effect with CsA and azathioprine.

Animals↗
PubMed1986

Eicosanoids, gamma-interferon and inflammatory cells in kidney transplant patients.

Urinary i-TXB2 of renal transplant patients was found to be unaffected by CsA administration. Thus CsA treatment is unlikely to contribute to false positive values in this diagnostic indicator of rejection. It is possible that CsA treatment may suppress the peak i-TXB2 attending rejection but this does not seem to be the case. Studies on rats with cardiac allografts show CsA not to attenuate the rejection i-TXB2 peak (8). The causal role of thromboxane in transplant rejection was further amplified by experimental studies in rats where the cardiac allograft was protected by thromboxane synthase inhibitors and receptor antagonists. The inflammatory cell infiltrate of clinical renal allografts correlated with urine i-TXB2. These data strengthens the diagnostic value of urine i-TXB2 as a non invasive indicator of transplant rejection. Serum gamma-interferon was studied in nine patients and detected for 14 and 10 consecutive days, respectively in 2 patients. Three of the remaining patients had mild rejection episodes. Of the two patients one rejected the kidney and the other had CMV infection. No correlation was found between gamma-interferon and urine-TXB2. Thus elevated serum gamma-interferon does not interfere with urine i-TXB2.

Animals↗
PubMed1985

Single-donor cold storage versus machine perfusion in cadaver kidney preservation.

Preservation of thirty-eight consecutive renal allograft donors was studied in a prospective, randomized protocol. Procurement was in-situ cooled, en-bloc nephrectomy accomplished by a single program. Nine pairs were deleted because of nonutilization of one kidney or change in mode of preservation. The remaining twenty nine pairs were implanted by twenty two institutions through usual organ sharing policies. Results showed that posttransplantation dialysis was required in 17% of machine-perfused and 63% of cold-stored allografts, which reached statistical significance (P less than 0.01). This increased number of dialyses in patients receiving the cold-stored kidneys offsets cost savings achieved through transporting cold stored allografts. This study shows machine-perfused renal allografts to be superior to paired, cold-stored allografts when analyzed with respect to early graft function.

Cadaver↗
PubMed1980

Serum beta-2-microglobulin: an adjunctive monitoring test in renal transplantation.

We have serially measured serum beta 2 M microglobulin in a series of transplant recipients along with other standard clinical parameters. Independent comparison of the beta 2 M results leads to the following conclusions: 1. Beta 2 M is superior to the Scr in detecting acute rejection, with diagnostic elevations occurring 2 to 7 days before Scr increase. The observation is valid for all rejection episodes. 2. Beta 2 M decreases prior to or simultaneously with the Scr following successful rejection therapy or beginning resolution of acute tubular necrosis. 3. Abnormal beta 2 M following rejection therapy invariably heralds another rejection episode within 10-20 days, despite the Scr having returned to baseline. 4. Beta 2 M remains normal in high grade ureteral obstruction despite increased Scr. 5. Beta 2 M is remarkably increased in patients with viremia, despite minimal change in Scr. Beta 2 M remains normal in lower UTI from bacterial origin. Beta 2 M appears to be a major contribution in the monitoring of the renal transplant recipient which may have significant impact on therapeutic decisions in the future. In addition, it provides a reliable in vitro parameter which can be used to further assess specific treatment variables in a prospective controlled protocol approach.

Antilymphocyte Serum↗